GLP-1 drugs and IPMN (pancreatic cysts)
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at how GLP-1 receptor agonists (medications used for diabetes and weight loss) might affect people with IPMN (a type of pancreatic cyst). The goal is to see if these drugs change the size or growth of the cysts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with IPMN (a type of pancreatic cyst) through imaging (CT or MRI).
- You are currently taking or have taken a GLP-1 receptor agonist (like Ozempic, Wegovy, Trulicity, or Mounjaro).
- You have signed a consent form allowing your medical data to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
This trial looks for markers in cyst fluid and tissue to help identify which IPMN growths are becoming invasive (spreading). It may help doctors decide who needs surgery.
This study collects information from people who have an IPMN cyst in the pancreas to help predict who may be at higher risk of pancreatic cancer. It may help your care team estimate risk and plan follow-up more effectively.
This study follows patients with a type of pancreatic cyst called IPMN who receive the LINFU procedure, a treatment that uses sound waves and microbubbles. Researchers want to see how well it works and monitor safety.
This trial tests a new method using an endoscope (a thin tube with a camera) to deliver a chemotherapy drug directly into a pancreatic cyst called IPMN. The goal is to see if this approach is safe and can prevent the cyst from growing or turning into cancer.
This study looks for new markers in the blood or tissues of people with a pancreatic condition called IPMN. The goal is to find better ways to predict if IPMN might turn into cancer and to help choose the best treatment.
Hear when a new IPMN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.